Detailed explanation of the role and efficacy of mobosetinib/mobosetinib

Mobocertinib is an oral targeted drug that is a tyrosine kinase inhibitor (TKI). It is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. This mutation is relatively rare in patients with non-small cell lung cancer, but it significantly affects the patient's prognosis because this mutation is highly resistant to conventional EGFR inhibitors (such as erlotinib, gefitinib, etc.). Mobosetinib inhibits the proliferation and metastasis of cancer cells by specifically inhibiting the kinase activity of this mutant EGFR.

The main mechanism of action of mobosetinib is through selective inhibitionEGFR exon 20 insertion mutation, which causes EGFR to be abnormally activated in non-small cell lung cancer cells and promotes the growth and spread of cancer cells. Compared with traditional EGFR-targeting drugs, mobosetinib can effectively overcome the drug resistance problem caused by exon 20 insertion mutations. Through this effect, mobosetinib provides a new treatment option for patients who are resistant to conventional EGFR inhibitors.

In terms of clinical efficacy, according to the results of the EXCLAIM clinical trialmobosetinib has demonstrated significant efficacy in the treatment of patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations. The drug had an objective response rate (ORR) of approximately 28%, while progression-free survival (PFS) was 7.3 months, and was well tolerated. While the efficacy of mobosertinib varies among individuals, its role in treating drug-resistant mutant non-small cell lung cancer has proven effective, particularly in patients who cannot be effectively controlled with conventional therapies.

However, although moboxetinib has shown good results in the treatment ofEGFR exon 20 insertion mutant non-small cell lung cancer, like all targeted drugs, it also has certain side effects, the most common of which include diarrhea, rash, loss of appetite and fatigue. A small number of patients may experience serious adverse reactions, such as liver function damage, lung problems, etc. Therefore, doctors need to closely monitor the patient's health status when using moboxetinib.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib